32 results
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
(except Japan) GB001 DP2 Antagonist (Oral) Chronic Rhinosinusitis (with and without nasal polyps) Worldwide (except Japan) GB001 DP2 Antagonist (Oral … ) Chronic Spontaneous Urticaria Worldwide (except Japan) GB002 PDGF Inhibitor (Inhaled) Pulmonary Arterial Hypertension Worldwide GB004 HIF-1α
8-K
EX-99.1
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
Exhibit 99.1
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
- Primary endpoint … , respectively; 23% improvement observed in 40 mg group -
- TITAN Study in chronic rhinosinusitis did not meet primary or secondary endpoints
8-K
EX-99.1
GOSS
Gossamer Bio Inc
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 -
- GB002: Expected to commence Phase 2 … Antagonist for Eosinophilic Asthma and Chronic Rhinosinusitis (CRS)
Phase 2b LEDA study in patients with moderate-to-severe eosinophilic asthma
8-K
EX-99.1
GOSS
Gossamer Bio Inc
24 Mar 20
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
8:45am
for Eosinophilic Asthma and Chronic Rhinosinusitis (CRS)
Gossamer has made available three poster presentations from its GB001 program for patients … of this year.
Enrollment in the ongoing Phase 2 TITAN proof-of-concept study in chronic rhinosinusitis, both with and without nasal polyps has been
8-K
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
13, 2020, the Company announced topline results from the Company’s Phase 2 trials in patients with moderate-to-severe eosinophilic asthma and chronic … .
The proof-of-concept TITAN trial enrolled 97 patients with chronic rhinosinusitis with and without nasal polyps and assessed treatment with GB001 40 mg vs
8-K
EX-99.2
jwd6xtme0vdwnr
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
pw0ypagx1cz0h n2
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
8-K
EX-99.1
vanm0nmeak16kmczalo
12 Nov 19
Gossamer Bio Announces Third Quarter 2019 Financial Results
4:10pm
8-K
EX-99.1
cq6etrgu
8 Aug 19
Gossamer Bio Announces Second Quarter 2019 Financial Results
4:10pm
8-K
EX-99.1
wxsu17cm
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
8-K
EX-99.1
hahitfmjs
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
10-K
wfd54qe elwx4b0c
22 Mar 19
Annual report
4:45pm
424B4
9ihz9g211z933dl 9kb
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
8a6 at0upy41937l5o
21 Dec 18
IPO registration
4:39pm
S-1/A
z7jwg shurgi
23 Jan 19
IPO registration (amended)
4:39pm
DRS/A
oo2j0c pivuufwh
29 Nov 18
Draft registration statement (amended)
12:00am
DRS
httm wtowedt
11 Oct 18
Draft registration statement
12:00am